Queiroz-Telles F et al., 2017. Chromoblastomycosis. Clin Microbiol Rev 30: 233–276.
Queiroz-Telles F, Santos DW, 2013. Challenges in the therapy of chromoblastomycosis. Mycopathologia 175: 477–488.
Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A, 2009. Chromoblastomycosis: An overview of clinical manifestations, diagnosis and treatment. Med Mycol 47: 3–15.
Moreno LF, Vicente VA, De Hoog S, 2018. Black yeasts in the omics era: Achievements and challenges.Med Mycol 56: 32–41.
Passero LFD, Cavallone IN, Belda W, 2021. Reviewing the etiologic agents, microbe-host relationship, immune response, diagnosis, and treatment in chromoblastomycosis. J Immunol Res 2021: 9742832.
Fransisca C, He Y, Chen Z, Liu H, Xi L, 2017. Molecular identification of chromoblastomycosis clinical isolates in Guangdong. Med Mycol 55: 851–858.
Chen Y, Li L, Zhang Z, Gao R, Ran X, Sun J, Zhang C, Liu X, Ran Y, 2024. Sporotrichosis: Using scanning electron microscopy to decipher the “blackish-red dot sign” observed under dermoscopy. Skin Res Technol 30: e13775.
Bonifaz A, Carrasco-Gerard E, Saúl A, 2001. Chromoblastomycosis: Clinical and mycologic experience of 51 cases. Mycoses 44: 1–7.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 894 | 894 | 93 |
Full Text Views | 19 | 19 | 7 |
PDF Downloads | 27 | 27 | 11 |
Chromoblastomycosis (CBM), a prevalent subcutaneous mycosis in tropical and subtropical regions caused by dematiaceous fungi, often presents as refractory lesions. This case report details a 63-year-old woman from Tianjin, China, with CBM caused by Cladophialophora carrionii after plant trauma. Successful treatment with itraconazole was performed. After 3 months, the lesions improved significantly. The case highlights the importance of accurate diagnosis and tailored antifungal therapy, as well as the need for long-term follow-up because of the chronic nature of the disease.
Financial support: This study was supported by the
Disclosure: This study was approved by the Ethics Committee of Peking University First Hospital and was performed in compliance with the Declaration of Helsinki. The patient signed the informed consent form to participate in the study.
Current contact information: Yalong Li, Yinggai Song, and Aiping Wang, Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China, Research Center for Medical Mycology, Peking University, Beijing, China, and National Clinical Research Center for Skin and Immune Diseases, Beijing, China, E-mails: yalongli0430@163.com, syg3515@163.com, and wangap516@163.com.
Queiroz-Telles F et al., 2017. Chromoblastomycosis. Clin Microbiol Rev 30: 233–276.
Queiroz-Telles F, Santos DW, 2013. Challenges in the therapy of chromoblastomycosis. Mycopathologia 175: 477–488.
Queiroz-Telles F, Esterre P, Perez-Blanco M, Vitale RG, Salgado CG, Bonifaz A, 2009. Chromoblastomycosis: An overview of clinical manifestations, diagnosis and treatment. Med Mycol 47: 3–15.
Moreno LF, Vicente VA, De Hoog S, 2018. Black yeasts in the omics era: Achievements and challenges.Med Mycol 56: 32–41.
Passero LFD, Cavallone IN, Belda W, 2021. Reviewing the etiologic agents, microbe-host relationship, immune response, diagnosis, and treatment in chromoblastomycosis. J Immunol Res 2021: 9742832.
Fransisca C, He Y, Chen Z, Liu H, Xi L, 2017. Molecular identification of chromoblastomycosis clinical isolates in Guangdong. Med Mycol 55: 851–858.
Chen Y, Li L, Zhang Z, Gao R, Ran X, Sun J, Zhang C, Liu X, Ran Y, 2024. Sporotrichosis: Using scanning electron microscopy to decipher the “blackish-red dot sign” observed under dermoscopy. Skin Res Technol 30: e13775.
Bonifaz A, Carrasco-Gerard E, Saúl A, 2001. Chromoblastomycosis: Clinical and mycologic experience of 51 cases. Mycoses 44: 1–7.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 894 | 894 | 93 |
Full Text Views | 19 | 19 | 7 |
PDF Downloads | 27 | 27 | 11 |